Savient Gets Nod To Fund Ch. 11 Sale With Cash Collateral

Law360, New York (October 16, 2013, 3:47 PM ET) -- A Delaware bankruptcy judge Wednesday gave Savient Pharmaceuticals Inc. the go-ahead to use cash collateral to fund its stay in Chapter 11, enabling the drug developer to proceed with a planned $55 million asset sale.

At a hearing in Wilmington, U.S. Bankruptcy Judge Mary F. Walrath signed off on the cash-collateral motion and other pleadings designed to keep Savient up and running while it pursues a stalking horse sale to Sloan Holdings CV, a unit of US WorldMeds LLC.

“This case is about selling the business,”...
To view the full article, register now.

Dewey Verdict Watch

Follow our exclusive coverage of the trial of the year:

Click here for the latest